About Multiple Sclerosis Stem Cell Treatments
What the treatment consists of
The treatment primarily involves the use of Mesenchymal Stem Cells (MSCs) derived from sources such as bone marrow or umbilical cord tissue. These cells are administered to the patient—with the aim of modulating the immune response, reducing inflammation, promoting neuroprotection and potentially repairing damaged myelin in the central nervous system.
In some approaches, autologous hematopoietic stem cell transplantation (HSCT) is used: the patient’s immune system is “reset” and the stem cells (from bone marrow or peripheral blood) are re-infused to rebuild a healthier immune system. Research centers such as the Mayo Clinic mention this strategy for aggressive MS cases.
Treatment is delivered via different routes depending on the protocol: intravenous infusion, sometimes intrathecal (via lumbar puncture) or intraventricular for direct CNS delivery in research settings. The aim is to reach central nervous system tissue, where myelin damage occurs in MS.
Safety profiles in published clinical trials show generally mild adverse events (e.g., headache, fever) and no major complications in many cases, but the studies are heterogeneous and follow-up durations are limited.
Some ongoing research is exploring stem cell-derived extracellular vesicles (EVs) or secretomes as a possible safer, less invasive alternative to cell transplantation, especially in MS animal models where they showed reductions in inflammation and demyelination.
Questions and Answers:
Multiple Sclerosis Stem Cell Treatments
Q: Is this treatment approved for MS?
A: No, stem cell treatment for MS remains largely experimental. Clinical studies and systematic reviews show potential but long-term efficacy and standardized protocols are still under investigation.
Q: What mechanisms support stem cell therapy in MS?
A: MSCs have immunomodulatory properties—such as increasing regulatory T cells (Tregs), reducing pro-inflammatory Th17 cells—and may reduce lesion activity on MRI and improve disability scores like the Expanded Disability Status Scale (EDSS).
Q: What are the outcomes of these therapies?
A: Meta-analysis data indicate that approximately 40.4% of patients improved, 32.8% remained stable, and 18.1% worsened after MSC therapy in MS.
Q: Are there risks or limitations?
A: Yes. Key limitations include: small sample sizes, lack of long-term data, varied cell sources and administration protocols, and the fact that this is not standard of care. Some clinics offering unproven treatments have been flagged by regulators.
Q: Can these treatments reverse damage in MS?
A: There is currently no strong evidence that they reliably reverse all damage. The focus is more on halting progression and reducing new lesions. Repair of existing neurologic damage remains challenging.